CASI Pharmaceuticals, Inc. (NASDAQ:CASI – Get Rating) – Investment analysts at HC Wainwright lifted their Q2 2023 EPS estimates for shares of CASI Pharmaceuticals in a report released on Monday, May 22nd. HC Wainwright analyst S. Lee now forecasts that the biotechnology company will post earnings per share of ($0.50) for the quarter, up from their previous estimate of ($0.61). The consensus estimate for CASI Pharmaceuticals’ current full-year earnings is ($1.88) per share. HC Wainwright also issued estimates for CASI Pharmaceuticals’ Q3 2023 earnings at ($0.50) EPS, Q4 2023 earnings at ($0.35) EPS, FY2023 earnings at ($1.88) EPS and FY2024 earnings at ($0.45) EPS.
Separately, StockNews.com initiated coverage on shares of CASI Pharmaceuticals in a research note on Sunday, May 21st. They issued a “hold” rating on the stock.
CASI Pharmaceuticals Trading Up 12.1 %
Institutional Inflows and Outflows
Several hedge funds have recently modified their holdings of the business. Wellington Shields Capital Management LLC bought a new position in CASI Pharmaceuticals during the 1st quarter worth approximately $418,000. Wellington Shields & Co. LLC bought a new position in CASI Pharmaceuticals during the 1st quarter worth approximately $323,000. Susquehanna International Group LLP boosted its stake in CASI Pharmaceuticals by 70.6% during the 4th quarter. Susquehanna International Group LLP now owns 57,395 shares of the biotechnology company’s stock worth $100,000 after acquiring an additional 23,758 shares during the last quarter. Renaissance Technologies LLC bought a new position in CASI Pharmaceuticals during the 3rd quarter worth approximately $27,000. Finally, Prudential Financial Inc. bought a new position in CASI Pharmaceuticals during the 3rd quarter worth approximately $29,000. Institutional investors own 14.62% of the company’s stock.
CASI Pharmaceuticals Company Profile
CASI Pharmaceuticals, Inc engages in developing and commercializing therapeutics and pharmaceutical products. The company was founded on January 10, 2023 and is headquartered in Beijing, China.
- Get a free copy of the StockNews.com research report on CASI Pharmaceuticals (CASI)
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
- Best Buy’s Comeback Is Still At Play, Earnings Call For Patience
- e.l.f. Beauty Has Giant Quarter, Shares Hit New High
- If You Can Only Pick One Stock For The Rest Of 2023, Pick Nvidia
Receive News & Ratings for CASI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.